Hereditary thrombocytopenia
Conditions
Interventions
Observation group:None
Sponsors
Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Platelet count (PLT) is decreased as indicated by at least two complete blood count (CBC) tests, i.e., PLT < 100×10^9/L; 2.The etiology of thrombocytopenia remains unclear; 3.Patients with hematological malignancies who have not yet received chemotherapy or allogeneic stem cell transplantation.
Exclusion criteria
Exclusion criteria: 1.Patients with chemotherapy-induced thrombocytopenia (CTIT) due to malignant tumor treatment; 2.Patients with heparin or heparin-like substance-induced thrombocytopenia that resolves upon drug discontinuation; 3.Patients with liver cirrhosis or liver cancer complicated by thrombocytopenia; 4.Patients with acute trauma showing decreased platelet count confirmed by two consecutive complete blood count (CBC) tests within a short period; 5.Patients with acute or chronic hematological malignancies who have received drug therapy or allogeneic stem cell transplantation; 6.Patients with immune thrombocytopenic purpura (ITP) who respond well to immunosuppressive agents or hormone therapy; 7.Patients who have undergone whole-exome sequencing (WES) at other hospitals and whose thrombocytopenia has been confirmed to be non-hereditary; 8.Individuals currently participating in other clinical trials; 9.Individuals deemed ineligible for this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Deoxyribonucleic acid, DNA; | — |
Countries
China
Contacts
Public ContactChen Li
Second Affiliated Hospital of Army Medical University
Outcome results
None listed